What we could do now: molecular pathology of bladder cancer.
There is much information on the genetic alterations that contribute to the development of bladder cancer. Because it is hypothesised that the genotype of the cancer cell plays a major role in determining phenotype, this genetic information should impact on clinical practice. To date however, this has not happened. Some of the alterations identified in bladder cancer have clear associations with outcome-for example, mutational inactivation of the cell cycle regulator proteins p53 and the retinoblastoma protein (Rb). However, as single markers, these events have insufficient predictive power to be applied in the management of individual patients. The use of panels of markers is a potential solution to this problem. Examples of suitable panels include those genes/proteins with known impact on specific cell cycle checkpoints or with impact on cellular phenotypes, such as immortalisation, invasion, or metastasis. To evaluate such marker panels, large tumour series will be needed-for example, archival samples from completed clinical trials. The use of these valuable resources will require coordination of sample provision. This might involve central collection and distribution of tissue blocks, sections, or tissue arrays and the provision of patient follow up information to laboratories participating in a study. With the availability of microarray technologies, including cDNA and comparative genomic hybridisation arrays, the transcriptome and genome of transitional cell carcinomas of different phenotypes can be compared and will undoubtedly provide a wealth of information with potential diagnostic and prognostic uses. Although these studies can be initiated using small local tissue collections, high quality collection of fresh tissues from new clinical trials will be crucial for proper evaluation of associations with clinical outcome. Funding for molecular pathological studies to date has been poor. To begin to translate molecular information from the laboratory to the clinic and to make maximum use of valuable urological patient resources in the UK, adequate funding and scientific energy are required. Whereas the latter is not in doubt, present funding for this type of translational research is inadequate.
Knowles
M A
MA
ICRF Clinical Centre in Leeds, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. m.knowles@icrf.icnet.uk
D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D019938:Cyclin D1 / Q000235:genetics; D017353:Gene Deletion; D016161:Genes, Retinoblastoma; D019942:Genes, p16; D016158:Genes, p53; D005819:Genetic Markers; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D011379:Prognosis; D011506:Proteins; D012106:Research; D025803:Tumor Suppressor Protein p14ARF; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy
D005819:Genetic Markers; D011506:Proteins; D025803:Tumor Suppressor Protein p14ARF; D019938:Cyclin D1